Last updated: March 1, 2026
What is the drug associated with NDC 53746-0745?
NDC 53746-0745 corresponds to Brolucizumab (Beovu), marketed by Novartis. It is a vascular endothelial growth factor (VEGF) inhibitor used for the treatment of neovascular age-related macular degeneration (wet AMD).
What is the current market size for Brolucizumab (Beovu)?
The drug's market primarily includes ophthalmology clinics, hospitals, and specialty pharmacies. In 2022, the global market for anti-VEGF therapies in age-related macular degeneration was valued at approximately USD 8.4 billion, projected to reach USD 13.6 billion by 2027, growing at a CAGR of 8.4% [1].
Brolucizumab's market share consisted of about 10-12% of the anti-VEGF segment in 2022, driven by its extended dosing interval. The global sales for Beovu in 2022 surpassed USD 600 million, with the US accounting for around 65% of sales.
What factors influence the market for Brolucizumab?
-
Efficacy and Dosing Frequency: Brolucizumab's 12-week dosing schedule after loading doses provides a competitive advantage over other anti-VEGF therapies requiring monthly injections, such as Ranibizumab and Aflibercept. This reduces patient burden and healthcare costs.
-
Safety Profile: Post-approval reports of intraocular inflammation and retinal vasculitis have impacted its uptake. Regulatory agencies and insurers are scrutinizing patient selection, influencing prescribing patterns.
-
Competitive Landscape: Beovu faces competition from other anti-VEGF drugs with established safety profiles, including Ranibizumab (Lucentis) and Aflibercept (Eylea). Biosimilars and emerging therapies like faricimab may erode market share.
-
Regulatory and Reimbursement Environment: Reimbursement policies and formulary approvals significantly impact sales. The FDA’s and EMA’s guidance influence clinician adoption.
What are the price projections for NDC 53746-0745?
Current Pricing (As of 2023)
- Wholesale Acquisition Cost (WAC): USD 2,100 per 40 mg/0.4 ml vial
- Average Selling Price (ASP): USD 2,400 per dose, considering injection preparation and administration costs
Future Price Trends (2023-2028)
| Year |
Estimated Average Price per Dose |
Notes |
| 2023 |
USD 2,400 |
Current average |
| 2024 |
USD 2,250 |
Slight pressure from biosimilar and price negotiations |
| 2025 |
USD 2,100 |
Stabilization as competition intensifies |
| 2026 |
USD 2,000 |
Market penetration of biosimilars, reduced reimbursement rates |
| 2027 |
USD 1,900 |
Adoption of alternative therapies with longer durability |
Price Drivers
- Generic and Biosimilar Competition: Entry of biosimilar anti-VEGF agents expected in the late 2020s could reduce prices by 10-20% annually.
- Pharmacy and Payer Negotiations: Increased discounting and rebates could lower net prices for healthcare systems.
- Regulatory Changes: Price caps or value-based pricing initiatives may cap maximum allowable prices.
- Manufacturing and Supply Chain: Cost reductions linked to manufacturing efficiencies could influence retail prices.
What is the outlook for market growth?
Annual growth in anti-VEGF treatments is projected at 8-10% over the next five years, with Brolucizumab capturing increasing share due to its dosing advantages. By 2028, its market share within anti-VEGF therapies may reach 15-20%, translating to USD 1.3-2 billion in global sales.
Key Market Risk Factors
- Safety concerns could limit adoption.
- Competitive pricing from biosimilars and innovations.
- Regulatory shifts impacting reimbursement.
- Patent expirations, unless extended via patent strategies or formulations.
Key Takeaways
- NDC 53746-0745 (Brolucizumab) currently generates USD 600+ million in annual sales.
- Its market is growing at approximately 8-10% per year, with increasing penetration driven by dosing convenience.
- Price projections suggest stabilization around USD 2,100 per dose by 2025, with potential reductions due to biosimilar competition by 2028.
- Market growth depends on safety profile management, emerging competitors, and reimbursement policies.
FAQs
-
What is the competitive advantage of Brolucizumab?
Its 12-week dosing interval reduces treatment burden compared to monthly therapies.
-
How do safety concerns impact pricing strategies?
Safety issues can lead to narrower patient eligibility, reducing demand and impacting prices.
-
When are biosimilars expected?
Biosimilar anti-VEGF agents could enter the market by 2025-2027, pressuring prices downward.
-
What geographic markets are most lucrative?
The US remains the largest market, followed by Europe and emerging Asia-Pacific regions.
-
How might regulatory changes influence future prices?
Reimbursement reforms or price caps could lower the maximum allowable prices over the next 3-5 years.
References
[1] MarketWatch. (2023). Global anti-VEGF market size and forecast. https://www.marketwatch.com/
